News

The TCN-202 is an antibody in development for the treatment of human cytomegalovirus (CMV) infection. Theraclone Sciences CEO Clifford Stocks said TCN-202 was discovered using Theraclone’s I-STAR platform,

The study enrolled 29 patients, suffered from a variety of solid tumors, including cervical, gastric, melanoma, non-small cell lung (NSCLD), ovarian, pancreatic, prostate, thyroid, urachal and uterine cancers.

The Phase III trial evaluated the efficacy, safety and tolerability of 40mg/1ml GA administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.

The collaboration is expected to exhance the GastroPlus simulation model for drug dosing in the oral cavity, such as sublingual, lingual and bucca dosing through a variety of

Innovimmune research team of autoimmune and immunoinflammation diseases has discovered oral small molecule cytokine inhibitors that exhibit a novel mode of binding to MIF. Innovimmune President and CEO

The (Oroeze) Benzydamine 0.15% w/v Oromucosal spray is available in the Teva 360 livery. The new product is a version of Difflam (Benzydamine) from Meda Pharmaceuticals. Teva commercial

Linagliptin, which is approved in the US, the European Union, Japan and other countries, including India, is an original research product of Boehringer. Lilly India managing director Melt

The vaccine, which is approved for use in children aged six weeks through 18 months, is indicated to prevent invasive disease caused by Neisseria meningitidis serogroups C and

Potelligent Chok1SV which manufactures recombinant antibodies will be a host cell line. The technology will include BioWa’s glycosylation Potelligent Technology and Lonza’s GS Gene Expression System in the